Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of "Buy" from Brokerages

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have been given an average rating of "Buy" by the thirteen analysts that are covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a buy recommendation and four have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $15.80.

Several research firms have recently issued reports on SLDB. JMP Securities started coverage on shares of Solid Biosciences in a report on Tuesday, December 10th. They set an "outperform" rating and a $15.00 target price for the company. Wedbush assumed coverage on shares of Solid Biosciences in a research report on Friday, December 13th. They set an "outperform" rating and a $16.00 price target for the company. Citizens Jmp raised shares of Solid Biosciences to a "strong-buy" rating in a research report on Tuesday, December 10th. Truist Financial assumed coverage on shares of Solid Biosciences in a research report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 target price for the company. Finally, HC Wainwright lifted their target price on shares of Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday.

Institutional Investors Weigh In On Solid Biosciences

A number of hedge funds have recently modified their holdings of the business. Vestal Point Capital LP grew its position in shares of Solid Biosciences by 1.8% during the 4th quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company's stock valued at $11,400,000 after acquiring an additional 50,000 shares during the period. Redmile Group LLC purchased a new position in shares of Solid Biosciences during the 4th quarter valued at $2,461,000. D. E. Shaw & Co. Inc. purchased a new position in shares of Solid Biosciences during the 4th quarter valued at $208,000. Corton Capital Inc. purchased a new position in shares of Solid Biosciences during the 4th quarter valued at $41,000. Finally, Cubist Systematic Strategies LLC lifted its stake in shares of Solid Biosciences by 479.4% during the 4th quarter. Cubist Systematic Strategies LLC now owns 65,613 shares of the company's stock valued at $262,000 after buying an additional 54,288 shares in the last quarter. Institutional investors own 81.46% of the company's stock.

Solid Biosciences Price Performance

Shares of SLDB opened at $5.73 on Thursday. The company has a 50-day simple moving average of $4.12 and a two-hundred day simple moving average of $5.47. Solid Biosciences has a one year low of $2.88 and a one year high of $15.05. The firm has a market capitalization of $437.31 million, a PE ratio of -1.88 and a beta of 1.98.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads